Research Grade Tifcemalimab

Catalog No.

DHJ14401

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Chimeric

Isotype

IgG4-kappa

Clonality

Monoclonal

Target

B- and T-lymphocyte attenuator, BTLA, CD272, B- and T-lymphocyte-associated protein

Concentration

2.61 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q7Z6A9

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

JS004, Icatolimab, CAS: 2236068-83-8

Clone ID

Tifcemalimab

Tifcemalimab as monotherapy or in combination with toripalimab in patients with relapsed/refractory lymphoma: a Phase I trial., PMID:40379637

Phase I/II Study of Tifcemalimab, an Anti-B and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer., PMID:40378060

Perioperative the BTLA inhibitor (tifcemalimab) combined with toripalimab and chemotherapy for resectable locally advanced thoracic esophageal squamous cell carcinoma trial (BT-NICE trial): a prospective, single-arm, exploratory study., PMID:40276504

Beyond the anti-PD-1/PD-L1 era: promising role of the BTLA/HVEM axis as a future target for cancer immunotherapy., PMID:37649037

Document Download

Research Grade Tifcemalimab.pdf